Assessing the efficacy of melatonin to curtail benzodiazepine/Z drugabuse

Autores
Cardinali, Daniel Pedro; Golombek, Diego A.; Rosenstein, Ruth E.; Brusco, Luis I.; Vigo, Daniel Eduardo
Año de publicación
2016
Idioma
inglés
Tipo de recurso
artículo
Estado
versión aceptada
Descripción
Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Instituto de Investigaciones Biomédicas; Argentina
Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina
Fil: Cardinali, Daniel Pedro. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Bioquímica Humana. Laboratorio de Neuroquímica Retiniana y Oftalmología Experimental; Argentina
Fil: Golombek, Diego A. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología; Argentina
Fil: Golombek, Diego A. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Bioquímica Humana. Laboratorio de Neuroquímica Retiniana y Oftalmología Experimental; Argentina
Fil: Rosenstein, Ruth E. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología; Argentina
Fil: Rosenstein, Ruth E. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Bioquímica Humana. Laboratorio de Neuroquímica Retiniana y Oftalmología Experimental; Argentina
Fil: Brusco, Luis I. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas José de San Martín. Centro de Neuropsiquiatría y Neurología de la Conducta; Argentina
Fil: Brusco, Luis I. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Bioquímica Humana. Laboratorio de Neuroquímica Retiniana y Oftalmología Experimental; Argentina
Fil: Vigo, Daniel Eduardo. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Instituto de Investigaciones Biomédicas; Argentina
Fil: Vigo, Daniel Eduardo. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina
Fil: Vigo, Daniel Eduardo. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Bioquímica Humana. Laboratorio de Neuroquímica Retiniana y Oftalmología Experimental; Argentina
Abstract: The abuse of benzodiazepine (BZP) and Z drugs has become, due to the tolerance and dependence theyproduce, a serious public health problem. Thirty years ago, we demonstrated in experimental animalsthe interaction of melatonin with central BZD receptors, and in 1997 we published the first series ofelderly patients who reduced BZP consumption after melatonin treatment. Almost every single neuron inthe hypothalamic suprachiasmatic nuclei (SCN), the central pacemaker of the circadian system, contains-aminobutyric acid (GABA) and many results in animals point out to a melatonin interaction with GABA-containing neurons. In addition, central-type BZD antagonism, that obliterates GABAAreceptor function,blunted most behavioral effects of melatonin including sleep. Melatonin is involved in the regulation ofhuman sleep. This is supported by the temporal relationship between the rise of plasma melatonin levelsand sleep propensity as well as by the sleep-promoting effects of exogenously administered melatonin.Both meta-analyses and consensus agreements give support to the therapeutic use of melatonin in sleepdisorders. This action is attributed to MT1and MT2melatoninergic receptors localized in the SCN, as wellas in other brain areas. This review discusses available data on the efficacy of melatonin to curtail chronicBZD/Z drug use in insomnia patients. A major advantage is that melatonin has a very safe profile, it isusually remarkably well tolerated and, in some studies, it has been administered to patients at very largedoses and for long periods of time, without any potentiality of abuse. Further studies on this applicationof melatonin are warranted.
Fuente
Pharmacological Research Vol. 109, 2016
Materia
MEDICINA
INSOMNIO
MELATONINA
SUEÑO
BIOMEDICINA
BENZODIACEPINAS
ABUSO DE DROGAS
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/4.0/
Repositorio
Repositorio Institucional (UCA)
Institución
Pontificia Universidad Católica Argentina
OAI Identificador
oai:ucacris:123456789/1465
Acceder
id RIUCA_e9dbe4a2310e3d4dd4dabca67c6f0d35
oai_identifier_str oai:ucacris:123456789/1465
network_acronym_str RIUCA
repository_id_str 2585
network_name_str Repositorio Institucional (UCA)
spelling Assessing the efficacy of melatonin to curtail benzodiazepine/Z drugabuseCardinali, Daniel PedroGolombek, Diego A.Rosenstein, Ruth E.Brusco, Luis I.Vigo, Daniel EduardoMEDICINAINSOMNIOMELATONINASUEÑOBIOMEDICINABENZODIACEPINASABUSO DE DROGASFil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Instituto de Investigaciones Biomédicas; ArgentinaFil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; ArgentinaFil: Cardinali, Daniel Pedro. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Bioquímica Humana. Laboratorio de Neuroquímica Retiniana y Oftalmología Experimental; ArgentinaFil: Golombek, Diego A. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología; ArgentinaFil: Golombek, Diego A. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Bioquímica Humana. Laboratorio de Neuroquímica Retiniana y Oftalmología Experimental; ArgentinaFil: Rosenstein, Ruth E. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología; ArgentinaFil: Rosenstein, Ruth E. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Bioquímica Humana. Laboratorio de Neuroquímica Retiniana y Oftalmología Experimental; ArgentinaFil: Brusco, Luis I. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas José de San Martín. Centro de Neuropsiquiatría y Neurología de la Conducta; ArgentinaFil: Brusco, Luis I. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Bioquímica Humana. Laboratorio de Neuroquímica Retiniana y Oftalmología Experimental; ArgentinaFil: Vigo, Daniel Eduardo. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Instituto de Investigaciones Biomédicas; ArgentinaFil: Vigo, Daniel Eduardo. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; ArgentinaFil: Vigo, Daniel Eduardo. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Bioquímica Humana. Laboratorio de Neuroquímica Retiniana y Oftalmología Experimental; ArgentinaAbstract: The abuse of benzodiazepine (BZP) and Z drugs has become, due to the tolerance and dependence theyproduce, a serious public health problem. Thirty years ago, we demonstrated in experimental animalsthe interaction of melatonin with central BZD receptors, and in 1997 we published the first series ofelderly patients who reduced BZP consumption after melatonin treatment. Almost every single neuron inthe hypothalamic suprachiasmatic nuclei (SCN), the central pacemaker of the circadian system, contains-aminobutyric acid (GABA) and many results in animals point out to a melatonin interaction with GABA-containing neurons. In addition, central-type BZD antagonism, that obliterates GABAAreceptor function,blunted most behavioral effects of melatonin including sleep. Melatonin is involved in the regulation ofhuman sleep. This is supported by the temporal relationship between the rise of plasma melatonin levelsand sleep propensity as well as by the sleep-promoting effects of exogenously administered melatonin.Both meta-analyses and consensus agreements give support to the therapeutic use of melatonin in sleepdisorders. This action is attributed to MT1and MT2melatoninergic receptors localized in the SCN, as wellas in other brain areas. This review discusses available data on the efficacy of melatonin to curtail chronicBZD/Z drug use in insomnia patients. A major advantage is that melatonin has a very safe profile, it isusually remarkably well tolerated and, in some studies, it has been administered to patients at very largedoses and for long periods of time, without any potentiality of abuse. Further studies on this applicationof melatonin are warranted.Elsevier2016info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttps://repositorio.uca.edu.ar/handle/123456789/14651096-1186 (online)1043-6618 (impreso)10.1016/j.phrs.2015.08.016Cardinali D. P., et al. Assessing the efficacy of melatonin to curtail benzodiazepine/Z drugabuse [en línea]. Postprint del documento publicado en Pharmacological Research. 2016, 109. doi: 10.1016/j.phrs.2015.08.016. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1465Pharmacological Research Vol. 109, 2016reponame:Repositorio Institucional (UCA)instname:Pontificia Universidad Católica Argentinaengenginfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/4.0/2025-07-03T10:55:17Zoai:ucacris:123456789/1465instacron:UCAInstitucionalhttps://repositorio.uca.edu.ar/Universidad privadaNo correspondehttps://repositorio.uca.edu.ar/oaiclaudia_fernandez@uca.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:25852025-07-03 10:55:17.95Repositorio Institucional (UCA) - Pontificia Universidad Católica Argentinafalse
dc.title.none.fl_str_mv Assessing the efficacy of melatonin to curtail benzodiazepine/Z drugabuse
title Assessing the efficacy of melatonin to curtail benzodiazepine/Z drugabuse
spellingShingle Assessing the efficacy of melatonin to curtail benzodiazepine/Z drugabuse
Cardinali, Daniel Pedro
MEDICINA
INSOMNIO
MELATONINA
SUEÑO
BIOMEDICINA
BENZODIACEPINAS
ABUSO DE DROGAS
title_short Assessing the efficacy of melatonin to curtail benzodiazepine/Z drugabuse
title_full Assessing the efficacy of melatonin to curtail benzodiazepine/Z drugabuse
title_fullStr Assessing the efficacy of melatonin to curtail benzodiazepine/Z drugabuse
title_full_unstemmed Assessing the efficacy of melatonin to curtail benzodiazepine/Z drugabuse
title_sort Assessing the efficacy of melatonin to curtail benzodiazepine/Z drugabuse
dc.creator.none.fl_str_mv Cardinali, Daniel Pedro
Golombek, Diego A.
Rosenstein, Ruth E.
Brusco, Luis I.
Vigo, Daniel Eduardo
author Cardinali, Daniel Pedro
author_facet Cardinali, Daniel Pedro
Golombek, Diego A.
Rosenstein, Ruth E.
Brusco, Luis I.
Vigo, Daniel Eduardo
author_role author
author2 Golombek, Diego A.
Rosenstein, Ruth E.
Brusco, Luis I.
Vigo, Daniel Eduardo
author2_role author
author
author
author
dc.subject.none.fl_str_mv MEDICINA
INSOMNIO
MELATONINA
SUEÑO
BIOMEDICINA
BENZODIACEPINAS
ABUSO DE DROGAS
topic MEDICINA
INSOMNIO
MELATONINA
SUEÑO
BIOMEDICINA
BENZODIACEPINAS
ABUSO DE DROGAS
dc.description.none.fl_txt_mv Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Instituto de Investigaciones Biomédicas; Argentina
Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina
Fil: Cardinali, Daniel Pedro. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Bioquímica Humana. Laboratorio de Neuroquímica Retiniana y Oftalmología Experimental; Argentina
Fil: Golombek, Diego A. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología; Argentina
Fil: Golombek, Diego A. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Bioquímica Humana. Laboratorio de Neuroquímica Retiniana y Oftalmología Experimental; Argentina
Fil: Rosenstein, Ruth E. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología; Argentina
Fil: Rosenstein, Ruth E. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Bioquímica Humana. Laboratorio de Neuroquímica Retiniana y Oftalmología Experimental; Argentina
Fil: Brusco, Luis I. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas José de San Martín. Centro de Neuropsiquiatría y Neurología de la Conducta; Argentina
Fil: Brusco, Luis I. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Bioquímica Humana. Laboratorio de Neuroquímica Retiniana y Oftalmología Experimental; Argentina
Fil: Vigo, Daniel Eduardo. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Instituto de Investigaciones Biomédicas; Argentina
Fil: Vigo, Daniel Eduardo. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina
Fil: Vigo, Daniel Eduardo. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Bioquímica Humana. Laboratorio de Neuroquímica Retiniana y Oftalmología Experimental; Argentina
Abstract: The abuse of benzodiazepine (BZP) and Z drugs has become, due to the tolerance and dependence theyproduce, a serious public health problem. Thirty years ago, we demonstrated in experimental animalsthe interaction of melatonin with central BZD receptors, and in 1997 we published the first series ofelderly patients who reduced BZP consumption after melatonin treatment. Almost every single neuron inthe hypothalamic suprachiasmatic nuclei (SCN), the central pacemaker of the circadian system, contains-aminobutyric acid (GABA) and many results in animals point out to a melatonin interaction with GABA-containing neurons. In addition, central-type BZD antagonism, that obliterates GABAAreceptor function,blunted most behavioral effects of melatonin including sleep. Melatonin is involved in the regulation ofhuman sleep. This is supported by the temporal relationship between the rise of plasma melatonin levelsand sleep propensity as well as by the sleep-promoting effects of exogenously administered melatonin.Both meta-analyses and consensus agreements give support to the therapeutic use of melatonin in sleepdisorders. This action is attributed to MT1and MT2melatoninergic receptors localized in the SCN, as wellas in other brain areas. This review discusses available data on the efficacy of melatonin to curtail chronicBZD/Z drug use in insomnia patients. A major advantage is that melatonin has a very safe profile, it isusually remarkably well tolerated and, in some studies, it has been administered to patients at very largedoses and for long periods of time, without any potentiality of abuse. Further studies on this applicationof melatonin are warranted.
description Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Instituto de Investigaciones Biomédicas; Argentina
publishDate 2016
dc.date.none.fl_str_mv 2016
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv https://repositorio.uca.edu.ar/handle/123456789/1465
1096-1186 (online)
1043-6618 (impreso)
10.1016/j.phrs.2015.08.016
Cardinali D. P., et al. Assessing the efficacy of melatonin to curtail benzodiazepine/Z drugabuse [en línea]. Postprint del documento publicado en Pharmacological Research. 2016, 109. doi: 10.1016/j.phrs.2015.08.016. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1465
url https://repositorio.uca.edu.ar/handle/123456789/1465
identifier_str_mv 1096-1186 (online)
1043-6618 (impreso)
10.1016/j.phrs.2015.08.016
Cardinali D. P., et al. Assessing the efficacy of melatonin to curtail benzodiazepine/Z drugabuse [en línea]. Postprint del documento publicado en Pharmacological Research. 2016, 109. doi: 10.1016/j.phrs.2015.08.016. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1465
dc.language.none.fl_str_mv eng
eng
language eng
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/4.0/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/4.0/
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv Pharmacological Research Vol. 109, 2016
reponame:Repositorio Institucional (UCA)
instname:Pontificia Universidad Católica Argentina
reponame_str Repositorio Institucional (UCA)
collection Repositorio Institucional (UCA)
instname_str Pontificia Universidad Católica Argentina
repository.name.fl_str_mv Repositorio Institucional (UCA) - Pontificia Universidad Católica Argentina
repository.mail.fl_str_mv claudia_fernandez@uca.edu.ar
_version_ 1836638330154909696
score 13.13397

Publicaciones similares